Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Non-randomized, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of S095029 (Anti-NKG2A Antibody) as a Part of Combination Therapy in Participants With Locally Advanced and Unresectable or Metastatic MSI-H/dMMR Gastro-esophageal Junction /Gastric Cancer

NCT06116136 is registered in ClinicalTrials.gov with Servier Bio-Innovation LLC as lead sponsor.

NCT NCT06116136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06116136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Non-randomized, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of S095029 (Anti-NKG2A Antibody) as a Part of Combination Therapy in Participants With Locally Advanced and Unresectable or Metastatic MSI-H/dMMR Gastro-esophageal Junction /Gastric Cancer
Lead sponsor
Servier Bio-Innovation LLC
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 31, 2024
Completion date
August 31, 2027
Enrollment
48 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

msi-h/dmmr gastric cancer, msi-h/dmmr gastroesophageal-junction cancer